Saturday, October 31, 2026

Private Credit Funds Freeze $1.7 Trillion Sector as US Asset Sales Hit Discounts, European Insurers Exit

Blue Owl Capital halted withdrawals from its retail private credit fund as the $1.7 trillion global sector faces liquidity restrictions. New Mountain Finance sold assets below reported valuations while European insurers AXA and Allianz signal reduced US private credit exposure amid valuation concerns.

Private Credit Funds Freeze $1.7 Trillion Sector as US Asset Sales Hit Discounts, European Insurers Exit
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Blue Owl Capital halted quarterly withdrawals from its retail private credit fund, joining liquidity restrictions across the $1.7 trillion global private credit sector. New Mountain Finance shares dropped to March 2020 levels following asset sales at discounts to reported valuations.

FS KKR Capital cut dividends while New Mountain sold assets below net asset values, raising questions about valuation accuracy across business development companies. Bank of America issued a buy rating on Blue Owl "amid misinformation"—defensive language that suggests positioning against market skepticism rather than fundamental conviction.

Withdrawal gates prevent redemptions when secondary market prices diverge from reported NAVs. Mark-to-model valuations allow managers to smooth portfolio values, but discounted asset sales expose gaps between reported and realizable prices—a pattern that historically precedes broader markdowns.

European insurers are reducing US private credit exposure. AXA's Thomas Buberl stated exposure sits "far below that of rivals." Allianz's Claire-Marie Coste-Lepoutre claimed the insurer feels "very comfortable" with its position. The messaging indicates concern about concentration risk as US rates remain elevated.

Gladstone Capital management said it "feels better about non-accrual names than a year ago" despite challenging M&A valuations—acknowledging valuation difficulties while claiming improvement. Non-accrual rates in quarterly filings will test whether optimism matches portfolio reality.

The $406 billion BDC sector faces pressure as higher-for-longer rates stress leveraged borrowers while exit valuations compress. Secondary market pricing for private credit funds trading at discounts to NAV suggests investors doubt reported valuations. Banking sector exposure through fund investments and warehouse lending creates spillover risks if portfolio stress accelerates.

Investors should compare reported NAVs against secondary market transaction prices. Covenant violation disclosures in quarterly filings and changes to independent valuation firms signal deteriorating credit quality before official write-downs appear. Previous credit cycles show withdrawal restrictions often precede valuation adjustments.


Sources:
1 Nasdaq, "4 ETFs Yielding Over 7% That Income Investors Are Quietly Buying" (March 22, 2026)
2 Globe Newswire, "Oracle Corporation (ORCL) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit -" (March 21, 2026)
3 Nasdaq, "Think You Can Ignore RMDs? Here's What It Could Cost You." (March 23, 2026)
4 Globe Newswire, "Indiaspora Releases Groundbreaking Report ‘India and its Diaspora: Partners in Progress’, Highlighti" (March 23, 2026)
5 Yahoo Finance, "Asian shares decline as hopes dim for resolution in Iran after Trump's latest comments" (March 23, 2026)

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com